Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-3
2023-503693-20-00Phase 3Withdrawn
- Sponsor
- Areteia Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Dexpramipexole + standard controller therapy with Placebo + standard controller therapy (2 arms). Primary endpoint: Annualized rate of severe asthma exacerbations (AAER) over 52 weeks. Planned start Sep 2023; status: withdrawn.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-503693-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503693-20-00.